US withdraws motion in Ranbaxy fraud investigation
This article was originally published in Scrip
Executive Summary
The US department of justice (DoJ) has withdrawn a motion seeking to force Ranbaxyto turn over documents in connection with an ongoing fraud investigation because it is satisfied that the requested information has been produced.